Evolve Private Wealth LLC Takes $3.58 Million Position in Envista Holdings Corporation $NVST

Evolve Private Wealth LLC purchased a new position in shares of Envista Holdings Corporation (NYSE:NVST) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 136,015 shares of the company’s stock, valued at approximately $3,584,000. Evolve Private Wealth LLC owned about 0.08% of Envista as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in NVST. GSA Capital Partners LLP purchased a new position in shares of Envista in the 2nd quarter valued at approximately $2,039,000. Pzena Investment Management LLC purchased a new stake in shares of Envista during the second quarter worth approximately $30,494,000. Dimensional Fund Advisors LP raised its stake in shares of Envista by 1.6% during the first quarter. Dimensional Fund Advisors LP now owns 9,780,948 shares of the company’s stock worth $248,130,000 after purchasing an additional 152,488 shares during the last quarter. SummitTX Capital L.P. acquired a new stake in shares of Envista during the first quarter worth $4,268,000. Finally, Royce & Associates LP lifted its holdings in shares of Envista by 11.6% during the fourth quarter. Royce & Associates LP now owns 996,147 shares of the company’s stock worth $21,626,000 after purchasing an additional 103,312 shares during the period.

Envista Trading Up 1.0%

Shares of NVST stock opened at $27.21 on Friday. The stock has a market cap of $4.37 billion, a P/E ratio of 46.91, a P/E/G ratio of 1.30 and a beta of 0.86. The company has a quick ratio of 2.07, a current ratio of 2.43 and a debt-to-equity ratio of 0.47. Envista Holdings Corporation has a fifty-two week low of $18.77 and a fifty-two week high of $30.42. The business has a fifty day simple moving average of $26.90 and a 200-day simple moving average of $26.28.

Envista (NYSE:NVST) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.34 by $0.07. The business had revenue of $730.50 million for the quarter, compared to analyst estimates of $716.11 million. Envista had a net margin of 3.33% and a return on equity of 7.88%. The business’s revenue for the quarter was up 7.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.26 EPS. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. On average, analysts forecast that Envista Holdings Corporation will post 1.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Barclays cut their price objective on shares of Envista from $34.00 to $32.00 and set an “overweight” rating for the company in a research report on Thursday, June 11th. BMO Capital Markets assumed coverage on shares of Envista in a research note on Wednesday, July 8th. They set a “market perform” rating and a $27.00 price target on the stock. Piper Sandler reiterated a “neutral” rating and set a $28.00 price target (up from $26.00) on shares of Envista in a research note on Thursday, August 6th. Morgan Stanley set a $23.00 price target on shares of Envista in a report on Thursday, August 6th. Finally, Wall Street Zen upgraded shares of Envista from a “buy” rating to a “strong-buy” rating in a research report on Saturday. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.31.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.